Skip to content
Axcess News – Lifestyle
Author:
ASCENTAGE PHARMA GROUP INTERNATIONAL
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
May 31, 2026
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
May 31, 2026
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
May 21, 2026
Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress
May 12, 2026
Ascentage Pharma to Participate in Three Upcoming Investor Conferences
May 12, 2026
←
Previous Page
1
2